Controversy exists about the safety of the parenteral iron dextran products, Dexferrum and INFeD, which
\nhave been associated with rare, serious anaphylactic-type reactions. In the United States, their product labels
\ncarry boxed warnings of this adverse event; some have called for the withdrawal from marketing of the higher
\nmolecular weight Dexferrum. Between 2002 and 2007, sales of Dexferrum, INFeD, and iron gluconate Ferrlecit
\ndeclined 32.5%, 21%, and 4.8%, respectively, while sales of iron sucrose Venofer increased 160%. Voluntary
\nreports submitted to the Food and Drug Administration show anaphylactic reactions and symptoms for the
\nfour parenteral iron products. Because of underreporting, possible differential reporting, absence of iron dextran
\nbrand names, and incomplete use (denominator) data, incidence rates and relative risk estimates cannot
\nbe calculated. U.S. death certificate data show that for most years from 1979 through 2006, no more than 3
\ndeaths per year were coded to \u2018\u2018adverse events in therapeutic use of iron preparations;\u2019\u2019 brand names were
\nnot consistently recorded. Emergency department data show small numbers of visits for treatment of allergic
\nreactions with intravenous iron preparations. The data presented herein show that allergic reactions are possible
\nwith all four parenteral iron products, and it is difficult to determine which product has the largest risk
\nbased on sales data, voluntarily submitted adverse event reports, death certificates, ED visits, and observational
\nstudies performed to date. To help differentiate risk among the parenteral iron products, the brand
\nname of the product always should be provided on medical records, death certificates, and adverse drug
\nreaction reports.<\/div>\n","protected":false},"excerpt":{"rendered":"

Editorial: Am. J. Hematol Fecha: 01\/09\/2010 Diane K. Wysowski,* Lynette Swartz, B. Vicky Borders-Hemphill,Margie R. Goulding and Catherine Dormitzer Acceso<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[4],"tags":[],"_links":{"self":[{"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/posts\/393"}],"collection":[{"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/comments?post=393"}],"version-history":[{"count":1,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/posts\/393\/revisions"}],"predecessor-version":[{"id":678,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/posts\/393\/revisions\/678"}],"wp:attachment":[{"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/media?parent=393"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/categories?post=393"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/tags?post=393"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}